Topiramate
Product Images NDC 53808-1132

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 53808-1132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 25mg (Topiramate 25mg)

Label Image For 25mg (Topiramate 25mg)
The label for Topiramate 25 mg tablets indicates a package quantity of 30 tablets. It is labeled as RX Only and manufactured by DOH Central Pharmacy, Tallahassee, FL 32304. The label also includes lot and expiration date details, a UPC barcode, and the term ZYGENERICS.*
FDA Label Image

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 01)

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 01)
Chemical structure of the active ingredient topiramate. The diagram shows the molecular structure including sulfonamide, ether groups, and multiple rings, consistent with topiramate's known formula.*
FDA Label Image

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 02)

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 02)
A Kaplan-Meier curve comparing cumulative rates to time to first seizure for two dosages of topiramate (50 mg/day and 400 mg/day) over approximately 500 days. The plot shows higher seizure delay rate with 400 mg/day compared to 50 mg/day, with a p-value of 0.0002 indicating statistical significance.*
FDA Label Image

Topiramate Tablets Usp (Af70d392 31a6 40bb 8f0a Ab51a70067fb 03)

Topiramate Tablets Usp (Af70d392 31a6 40bb 8f0a Ab51a70067fb 03)
Bar chart showing change from baseline to double-blind phase in average monthly migraine period rate (±SE) for placebo and topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day, across two studies. The chart includes significance indicators with p-values less than 0.010 and 0.001, comparing effects between placebo and different topiramate doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.